Regeneron Pharmaceuticals (REGN)

• Market cap: $78.8B
• 1 day: -0.11%
• 5 days: -1.85%
• 1 month: -7.15%
• 3 months: -0.91%
• 6 months: 30.25%
• Year to date: -3.93%
• 1 year: 9.57%
• 5 years: 54.1%
• 10 years: 99.79%
• Sector: Healthcare
• Industry: Biotechnology

About: Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).

Employees: 15,410